Target intelligence / Profile preview

PreS1 domain of hepatitis B virus large envelope protein (PreS1 domain)

Target
PreS1 domain
Molecular classification
Viral protein domain, Envelope protein domain, Intrinsically disordered protein region
01

Overview

The preS1 domain is a N-terminal extension of the large HBV surface protein (LHBs), comprising about 108 amino acids (variant depending on genotype). It is myristoylated at its N-terminus, which anchors the domain to the viral envelope. The domain mediates attachment to the hepatocyte-specific receptor, sodium taurocholate cotransporting polypeptide (NTCP), allowing HBV to enter liver cells. It also contains a fusion peptide motif critical for merging the viral envelope with host membranes during infection[2][3][5]. This domain is involved in interactions with the viral capsid for particle assembly, and its structural flexibility (intrinsic disorder) equips it to mediate various functions. Targeting preS1, with drugs or antibodies, is a validated approach to block HBV and hepatitis delta virus (HDV) entry, representing a promising antiviral strategy.[4][5]

Other names
Pre-S1preS1 regionpreS1 peptidepreS1 determinant
02

Mechanism of action

Blockade of NTCP binding, preventing viral entry; Inhibition of membrane fusion processes; Neutralization via anti-preS1 antibodies

03

Biological functions

Receptor binding at hepatocyte surface (NTCP interaction)Membrane fusionAttachment and entry into host cellsInteraction with viral capsid (in virion morphogenesis)Myristoylation-dependent cellular tropism
04

Disease associations

Infection (Hepatitis B, essential for productive infection and transmission)
05

Safety considerations

Off-target effects of entry inhibitors that interact with NTCP, potentially disturbing bile acid transportViral mutations in preS1 may alter its structure/function and affect therapeutic efficacyDisordered nature increases immune evasion, complicating vaccine/antibody approaches
06

Interacting drugs

Myrcludex B (now bulevirtide)

1 more in the full profile.

07

Biomarkers

preS1 antigen (used in some diagnostic and monitoring assays)HBV DNA and antigenemia in preS1-targeted therapies (efficacy monitoring)

Beyond the preview

Go deeper on PreS1 domain of hepatitis B virus large envelope protein (PreS1 domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreS1 domain of hepatitis B virus large envelope protein (PreS1 domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call